A message from our partners at SmallCaps Daily PMAX: A Hong Kong Financial Communications Powerhouse Offering U.S. Investors a Direct Line to Asia’s Multi-Trillion Dollar Capital Markets and Recurring Compliance Revenue. 
Powell Max Limited (NASDAQ: PMAX) operates at the heart of Hong Kong’s capital markets, serving more than 2,600 listed companies in a market valued at roughly $4.5 trillion. With IPOs, secondaryofferings, and mandatory corporate reporting creating predictable, recurring demand, PMAX has positioned itself as an indispensable partner for issuers navigating complex regulatory requirements. Its end-to-end services—from financial printing and bilingual translation to electronic filing and ESG reporting—mean clients rely on PMAX for accuracy, speed, and compliance every day. For U.S. investors, PMAX offers a rare way to tap into the growth of Asia’s capital markets without leaving the Nasdaq. The company’s recurring, compliance-driven revenue model makes it resilient to discretionary spending cycles, while recent leadership changes, a $17 million capital raise, and regained Nasdaq compliance signal a company ready to execute its next phase of growth. With a strong balance sheet and operational infrastructure, PMAX is positioned to capture ongoing transaction activity and maintain a dominant niche role in one of the world’s most active equity markets. Don’t let PMAX fly under the radar—dig in and see why this Hong Kong market leader could be the hidden gem your portfolio needs.
Monday's Featured News Patience Pays: Hims & Hers Surges on News of Novo Nordisk DealAuthor: Jordan Chussler. First Published: 3/10/2026. 
Key Points - Hims & Hers has shifted from offering controversial compounded GLP-1s to a formal agreement with Novo Nordisk, allowing the platform to distribute FDA-approved Ozempic and Wegovy.
- Following the announcement, HIMS shares surged nearly 46%, helping the stock recover from a 59% drop earlier in the year caused by previous legal friction with Novo Nordisk.
- Analysts have upgraded the stock, citing the partnership as a major growth catalyst; despite a year-to-date loss, earnings are projected to grow by over 79% next year.
- Special Report: Wall Street's quietly buying these 3 AI infrastructure plays
 After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is back in the spotlight. Shares surged after the company announced an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the same company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9. After pulling its compounded semaglutide product modeled on Novo Nordisk's weight-loss drugs Wegovy and Ozempic, Hims & Hers said in a press release that the two companies have entered a strategic partnership to make Novo Nordisk's obesity drugs available through Hims & Hers' telehealth platform. Since that announcement, HIMS has climbed nearly 46% and received analyst upgrades as Wall Street grows more bullish on the direct-to-consumer prescription drug provider. A Strategic Shift From Compounded GLP-1 to FDA-Approved Drugs Compounded GLP-1 alternatives emerged to meet surging demand and shortages for weight-loss drugs, but these formulations lack U.S. Food and Drug Administration (FDA) approval. While compounded options expanded access and often used the same active ingredients (for example, semaglutide and tirzepatide, the latter marketed as Mounjaro and Zepbound), the absence of FDA review means they were not evaluated for quality or consistent effectiveness. That creates risks such as incorrect dosing, improper storage, and other safety concerns. According to Hims & Hers's press release, as part of the company's shift away from compounded GLP-1 offerings, "existing patients will have the opportunity to transition to FDA-approved medicines." Specifically, "Hims & Hers has entered into an agreement with Novo Nordisk that will bring Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets." Co-founder and CEO Andrew Dudum said the deal should create "tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications." He added that the "collaboration reflects what's possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations." Shares of HIMS Are Still Struggling, But the Future Looks Promising Shareholders welcomed the news and the sharp price bump after a turbulent year for Hims & Hers. Even after the February sell-off tied to the Novo Nordisk dispute, some analysts remained optimistic, with certain 12-month price targets implying as much as 150% potential upside. Despite the March 9 surge, HIMS shares are still down nearly 33% over the past 12 months. Fundamentally, however, the company appears positioned to sustain growth. When Hims & Hers reported full-year and Q4 2025 earnings on Feb. 23, it posted an EPS beat but a slight revenue miss. EPS of $0.08 topped expectations of $0.02, while revenue of $617.82 million fell short of the $619.48 million forecast. It was the company's first EPS beat since the first quarter of last year. More importantly, the financials showed consistent revenue growth, with a three-year average of 64.60%. Although earnings contracted in 2025, that followed EPS growth of nearly 582% in 2024 and about 66% in 2023. Hims & Hers Health's earnings per share are expected to rise roughly 79.31% next year, from $0.29 to $0.52. HIMS Receives Analyst Upgrades as Wall Street Turns Bullish on Telehealth After the Novo Nordisk announcement, Bank of America Securities upgraded HIMS to Neutral from Underperform and raised its price target to $23 from $12.50. Importantly, the firm's prior price target excluded contributions from GLP-1 revenue, underscoring that the Novo Nordisk agreement is viewed as a meaningful catalyst by analysts. Overall, the stock has a consensus Hold rating based on 17 analysts covering the name. The average one-year price target implies more than 32% potential upside. Current short interest stands at 43.24% of shares outstanding and should be watched, but that figure—which equates to about $1.32 billion in shorted stock—is substantially lower than the $4.27 billion shorted last July. The downtrend has continued, and it would not be surprising to see institutional buyers increase their exposure in coming quarters as the Novo Nordisk deal supports top-line growth. | 
